# US 2019/0169214 A1 · Bisphosphonate quinolone conjugates and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169214 A1
- Document ID: US20190169214A1
- Status: Published application
- Kind: A1
- Application number: 16/207,465
- Filed: 2018-12-03
- Published: 2019-06-06
- Earliest claimed: 2016-06-03
- Assignees: Biovinc, LLC; University of Southern California
- Applicants: Biovinc, LLC; University of Southern California
- Inventors: Frank H. EBETINO; Shuting SUN; Mark W. LUNDY; Charles E. MCKENNA; Eric RICHARD; Parish SEDGHIZADEH; Keivan SADRERAFI; Philip T. CHERIAN
- Web page: https://patentgrep.com/patent/US20190169214A1

## CPC

- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- A61K 47/548: {Phosphates or phosphonates, e.g. bone-seeking (phospholipids A61K47/544)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/552: {one of the codrug's components being an antibiotic}
- A61P 19/10: for osteoporosis
- A61P 31/04: Antibacterial agents
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof that can include a bisphosphonate and a quinolone, where the quinolone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof.

## Claims

### Claim 1 (depends on 4)

The compound of claim 4, wherein the compound is according to Formula (6)

### Claim 2 (depends on 12)

The pharmaceutical formulation of claim 12, wherein the compound is according to Formula (6)

### Claim 3 (depends on 1)

A method of treating or preventing a bone infection in a subject in need thereof, the method comprising:
administering an amount of the compound of claim 1, or a pharmaceutical formulation comprising the compound of claim 1 and a pharmaceutically acceptable carrier, to the subject in need thereof.

### Claim 4

A compound comprising:
a bisphosphonate; and
a quinolone compound;
wherein the quinolone compound is releasably coupled to the bisphosphonate via a linker, wherein the linker is a carbamate linker.

### Claim 5 (depends on 4)

The compound of claim 4, wherein the bisphosphonate is selected from the group consisting of: hydroxyl phenyl alkyl or aryl bisphosphonates, hydroxyl phenyl (or aryl) alkyl hydroxyl bisphosphonates, amino phenyl(or aryl) alkyl bisphosphonates, amino phenyl(or aryl) alkyl hydroxyl bisphosphonates, hydroxyl alkyl bisphosphonates, hydroxyl alkyl hydroxyl bisphosphonates, hydroxyl alkyl phenyl(or aryl) alkyl bisphosphonates, hydroxyl phenyl(or aryl) alkyl hydroxyl bisphosphonates, amino phenyl(or aryl) alkyl bisphosphonates, amino phenyl(or aryl) alkyl hydroxyl bisphosphonates, hydroxyl alkyl bisphosphonates, hydroxyl alkyl hydroxyl bisphosphonates, hydroxypyridyl alkyl bisphosphonates, pyridyl alkyl bisphosphonates, hydroxyl imadazoyl alkyl bisphosphonates, imidazoyl alkyl bisphosphonates, etidronate, pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate, zoledronate, minodronate and combinations thereof, wherein all the compounds are optionally further substituted or are unsubstituted.

### Claim 6 (depends on 4)

The compound of claim 4, wherein the quinolone compound is selected from the group consisting of: alatrofloxacin, amifloxacin, balofloxacin, besifloxacin, cadazolid, ciprofloxacin, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, flerofloxacin, flumequine, gatifloxacin, gemifloxacin, grepafloxacin, ibafloxacin, JNJ-Q2, levofloxacin, lomefloxacin, marbofloxacin, moxifloxacin, nadifloxacin, norfloxacin, ofloxacin, orbifloxacin, pazufloxacin, pefloxacin, pradofloxacin, prulifloxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tosufloxacin, trvafloxacin, zabofloxacin, nemonoxacin and combinations thereof.

### Claim 7 (depends on 4)

The compound of claim 4, wherein the quinolone compound has a structure according to Formula A,
where R1 is one or more substituents selected from the group consisting of: an alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxyl, alkoxy, substituted alkoxy, phenoxy, substituted phenoxy, aroxy, substituted aroxy, alkylthio, substituted alkylthio, phenylthio, substituted phenylthio, arylthio, substituted arylthio, cyano, isocyano, substituted isocyano, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, sulfonyl, substituted sulfonyl, sulfonic acid, phosphoryl, substituted phosphoryl, phosphonyl, substituted phosphonyl, polyaryl, substituted polyaryl, C3-C20 cyclic, substituted C3-C20 cyclic, heterocyclic, substituted heterocyclic, amino acid, peptide, and polypeptide groups,
where R2 is selected from the group consisting of: an alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxyl, alkoxy, substituted alkoxy, phenoxy, substituted phenoxy, aroxy, substituted aroxy, alkylthio, substituted alkylthio, phenylthio, substituted phenylthio, arylthio, substituted arylthio, cyano, isocyano, substituted isocyano, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, sulfonyl, substituted sulfonyl, sulfonic acid, phosphoryl, substituted phosphoryl, phosphonyl, substituted phosphonyl, polyaryl, substituted polyaryl, C3-C20 cyclic, substituted C3-C20 cyclic, heterocyclic, substituted heterocyclic, amino acid, peptide, and polypeptide groups,
where R3 is selected from the group consisting of: an alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxyl, alkoxy, substituted alkoxy, phenoxy, substituted phenoxy, aroxy, substituted aroxy, alkylthio, substituted alkylthio, phenylthio, substituted phenylthio, arylthio, substituted arylthio, cyano, isocyano, substituted isocyano, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, sulfonyl, substituted sulfonyl, sulfonic acid, phosphoryl, substituted phosphoryl, phosphonyl, substituted phosphonyl, polyaryl, substituted polyaryl, C3-C20 cyclic, substituted C3-C20 cyclic, heterocyclic, substituted heterocyclic, amino acid, peptide, and polypeptide groups, and
where R4 is selected from the group consisting of: an alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halo, hydroxyl, alkoxy, substituted alkoxy, phenoxy, substituted phenoxy, aroxy, substituted aroxy, alkylthio, substituted alkylthio, phenylthio, substituted phenylthio, arylthio, substituted arylthio, cyano, isocyano, substituted isocyano, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, amino, substituted amino, amido, substituted amido, sulfonyl, substituted sulfonyl, sulfonic acid, phosphoryl, substituted phosphoryl, phosphonyl, substituted phosphonyl, polyaryl, substituted polyaryl, C3-C20 cyclic, substituted C3-C20 cyclic, heterocyclic, substituted heterocyclic, amino acid, peptide, and polypeptide groups.

### Claim 8 (depends on 4)

The compound of claim 4, wherein the linker is an aryl carbamate, an aryl thiocarbamate, an O-thioarylcarbamate, an S-thioarylcarbamate, a thiocarbamate, an O-thiocarbamate, an S-thiocarbamate, a phenyl carbamate, a phosphonyl carbamate, or an aryl or phosphonyl substituted carbamate linker.

### Claim 9 (depends on 8)

The compound of claim 8, wherein the linker is attached to the R1 group of Formula A.

### Claim 10 (depends on 4)

The compound of claim 4, wherein the bisphosphonate is ethylidenebisphosphonate and the alpha position of the ethylidenebisphosphonate is substituted by hydroxy, fluoro, chloro, bromo or iodo.

### Claim 11 (depends on 4)

The compound of claim 4, wherein the compound has a formula according to Formula (12):
a formula according to Formula (13)
a formula according to Formula (15)
a formula according to Formula (41)
or
a formula according to Formula (43)

### Claim 12 (depends on 4)

A pharmaceutical formulation comprising:
an amount of a compound as set forth in claim 4; and
a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The pharmaceutical formulation of claim 12, wherein the amount of the compound is an amount effective to kill or inhibit bacteria growth, to treat or prevent bone diseases with abnormal bone resorption, to treat or prevent bone infections, or to treat or prevent osteoporosis, osteomyelitis, osteonecrosis, peri-implantitis, and periodontitis

### Claim 14 (depends on 4)

A method of treating or preventing osteomyelitis in a subject in need thereof, the method comprising:
administering an amount of a compound claim 4, or a pharmaceutical formulation comprising a compound of claim 4 and a pharmaceutically acceptable carrier, to the subject in need thereof.

### Claim 15 (depends on 4)

A method of treating or preventing peri-implantitis or periodontitis in a subject in need thereof, the method comprising administering an amount of a compound as in claim 4, or a pharmaceutical formulation comprising a compound of claim 4 and a pharmaceutically acceptable carrier, to the subject in need thereof.

### Claim 16 (depends on 4)

A method of treating or preventing diabetic foot in a subject in need thereof, the method comprising administering an amount of a compound as in claim 4, or a pharmaceutical formulation comprising a compound of claim 4 and a pharmaceutically acceptable carrier, to the subject in need thereof.

### Claim 17 (depends on 4)

A bone graft composition comprising:
a bone graft material and a compound as in claim 4, or a pharmaceutical formulation comprising a compound of claim 4 and a pharmaceutically acceptable carrier, wherein the compound or pharmaceutical formulation is attached to, integrated with, chemisorbed to, or mixed with the bone graft material, or wherein the bone graft material is autograft bone material, allograft bone material, xenograft bone material, a synthetic bone graft material, or any combination thereof.

### Claim 18 (depends on 17)

A method comprising:
implanting the bone graft composition of claim 17 into a subject in need thereof.

### Claim 19 (depends on 4)

A method of treating or preventing biofilm infection at an osseous or implant surgical site, or at a surgical site where bone grafting is performed, where the method comprises:
administering a compound claim 4, or a pharmaceutical formulation comprising a compound of claim 4 and a pharmaceutically acceptable carrier, to a subject in need thereof.

### Claim 20 (depends on 17)

A method of treating or preventing biofilm infection at an osseous or implant surgical site, or at a surgical site where bone grafting is performed, where the method comprises:
implanting a bone graft composition as in claim 17 to a subject in need thereof.
